ICH Q6A Specifications: Tests and Decision Trees

ICH Quality Guideline | Pharmaceutical Quality

ICH Q6A Guideline: Specifications and Acceptance Criteria

A practical guide to test procedures, acceptance criteria, universal and specific tests, and the eight ICH Q6A decision trees for chemical drug substances and products.

ICH ICH Q6A guideline

new Tests and Decision Treesa

Source Version ICH Q6A Step 4, 6 October 1999

Quick definition: The ICH Q6A guideline explains how to establish specifications by selecting appropriate tests, analytical procedures, and scientifically justified acceptance criteria for new chemical drug substances and drug products.

Introduction

The ICH Q6A guideline provides a science-based framework for establishing specifications, analytical procedures, and acceptance criteria for new chemical drug substances and drug products. It explains how pharmaceutical manufacturers should select quality tests, justify numerical limits, and use development, stability, manufacturing, and clinical data to support regulatory submissions.

A specification is not simply a list of laboratory tests. It is a documented quality standard that connects the identity, strength, purity, performance, and safety of a drug substance or finished product with its intended use. The guideline also explains when tests such as particle-size distribution, polymorphism, microbial limits, dissolution, chiral purity, water content, or preservative content may be necessary.

The uploaded document is the ICH Q6A Step 4 version dated 6 October 1999. It covers synthetic chemical drug substances and drug products, including solid oral dosage forms, oral liquids, and parenteral products. Its eight decision trees provide practical pathways for setting acceptance criteria for impurities, degradation products, particle size, polymorphism, chiral quality, microbiological attributes, and dissolution.

This article summarizes the guideline and translates its technical principles into practical pharmaceutical quality and regulatory applications.

What Is the ICH Q6A Guideline?

The ICH Q6A guideline is titled “Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances.”

Its main objective is to support the development of consistent specifications for new chemical drug substances and drug products intended for marketing approval.

Definition of a Specification

According to the guideline, a specification consists of:

1. A list of tests
2. References to analytical procedures
3. Acceptance criteria for each test

Acceptance criteria may be expressed as:

• Numerical limits
• Ranges
• Pass/fail requirements
• Other scientifically justified measures

A drug substance or drug product conforms to specifications when it is tested using the listed procedures and meets the approved acceptance criteria.

Specification Versus Full Characterization

Specifications are intended to confirm the quality of a product during release and throughout its shelf life. They are not intended to repeat every characterization study conducted during development.

Characterization studies may include extensive investigations of:

• Molecular structure
• Solid-state properties
• Impurity profiles
• Particle morphology
• Degradation pathways
• Process behavior
• Stability mechanisms

Only the attributes that are relevant to quality, safety, efficacy, consistency, and product performance normally need to become part of the final specification.

Scope of ICH Q6A

Products Covered

The guideline is primarily intended for:

• New synthetic chemical drug substances
• New chemical drug products
• Combination products containing more than one drug substance
• Solid oral dosage forms
• Liquid oral dosage forms
• Small- and large-volume parenteral products

It may also be useful for other dosage forms, including:

• Inhalation products
• Topical creams, ointments, and gels
• Transdermal systems
• Suspensions and products requiring reconstitution

The dosage forms described in Q6A are representative models rather than a complete list of all possible products.

Products Generally Outside the Main Scope

The guideline is not sufficient by itself for:

• Higher molecular weight peptides
• Polypeptides
• Biotechnological and biological products
• Radiopharmaceuticals
• Fermentation products
• Oligonucleotides
• Herbal products
• Crude products of animal or plant origin

For biotechnological and biological products, a separate ICH specifications guideline, commonly known as Q6B, is more appropriate.

Development Stage Covered

ICH Q6A focuses on specifications for marketing approval. It does not primarily address drug substances or drug products during early clinical research.

However, development-stage data are essential because they provide the scientific basis for selecting and justifying final specifications.

Specifications as Part of a Total Control Strategy

A specification is only one part of the overall quality system. Reliable product quality also depends on:

• Product and process design
• Raw-material control
• Validated manufacturing processes
• Validated analytical methods
• In-process controls
• Stability testing
• Equipment qualification
• Cleaning and environmental controls
• Packaging and container-closure systems
• cGMP compliance

The quality system should be designed so that specifications verify the effectiveness of the broader control strategy rather than compensate for a poorly controlled process.

A product should not rely on end-product testing alone to achieve quality. Testing cannot fully correct weaknesses in formulation design, process control, equipment performance, or manufacturing discipline.

Universal and Specific Tests

ICH Q6A divides specification tests into two broad categories.

Category	Meaning	Examples
Universal tests	Tests potentially applicable to most or all new drug substances or products	Description, identification, assay, impurities
Specific tests	Tests selected according to the properties and intended use of a particular product	Particle size, dissolution, polymorphism, sterility, pH, viscosity

Universal tests are considered broadly applicable, but their methods and acceptance criteria still require product-specific justification.

Specific tests should be included only when the attribute has a meaningful effect on product quality, safety, efficacy, manufacturability, or performance.

Universal Tests for New Drug Substances

Description

The description test provides a qualitative statement about the physical appearance of the drug substance, such as:

• Solid or liquid state
• Color
• Physical form

Any significant change during storage should be investigated. The description should be sufficiently clear to identify unexpected changes in the material.

Identification

Identification testing should be specific enough to distinguish the drug substance from closely related compounds likely to be present.

Examples of suitable approaches include:

• Infrared spectroscopy
• Two chromatographic procedures based on different separation principles
• HPLC with UV diode-array detection
• HPLC coupled with mass spectrometry
• GC coupled with mass spectrometry

A single chromatographic retention time is generally not considered sufficiently specific by itself.

For salt forms, the identification method should confirm the relevant individual ions or specifically identify the salt form.

Assay

The assay determines the content or strength of the drug substance. A specific, stability-indicating analytical procedure should normally be used.

In many cases, one chromatographic method can be used for both:

• Assay of the drug substance
• Quantification of organic impurities

If a nonspecific assay, such as titration, is used, additional impurity procedures may be necessary to provide adequate overall specificity.

Impurities

Impurity controls may include:

• Organic impurities
• Inorganic impurities
• Residual solvents
• Specified identified impurities
• Specified unidentified impurities
• Total impurity limits

Impurity acceptance criteria should be based on development batches, process understanding, toxicological qualification, stability results, and expected manufacturing variability.

Universal Tests for New Drug Products

Description

The finished dosage form should be described using appropriate characteristics, such as:

• Dosage form
• Size
• Shape
• Color
• Surface appearance
• Clarity, where applicable

Changes during manufacture or storage should be investigated and addressed through suitable acceptance criteria.

Identification

Finished-product identification should confirm the identity of the active drug substance and distinguish it from likely related compounds.

A single retention time is generally insufficient as the only identity test. A combination of orthogonal analytical techniques may provide stronger specificity.

Assay

A stability-indicating assay should be included to determine the strength of the drug product.

Content uniformity results may be used to establish product strength when the analytical method is suitable for assay purposes and has adequate specificity and accuracy.

Degradation Products and Other Impurities

Drug-product impurity specifications should normally address:

• Degradation products formed from the drug substance
• Impurities formed during product manufacture
• Individual specified degradation products
• Unidentified degradation products, where appropriate
• Total degradation products

Process impurities from drug-substance synthesis are normally controlled through the drug-substance specification. They do not generally need to be repeated in the finished-product impurity limit unless they are also degradation products.

If development and stability studies conclusively demonstrate that the drug substance does not degrade in a specific formulation and container-closure system, degradation-product testing may be reduced or eliminated only with appropriate regulatory approval.

Specific Tests for New Drug Substances

Physicochemical Properties

Depending on the drug substance and its intended use, specific physicochemical tests may include:

• pH of an aqueous solution
• Melting point or melting range
• Refractive index
• Optical properties
• Solid-state characteristics

These tests should be selected according to the physical nature and functional use of the material.

Particle-Size Distribution

Particle-size testing may be necessary when particle size affects:

• Dissolution
• Solubility
• Bioavailability
• Processability
• Product stability
• Content uniformity
• Appearance

The Q6A particle-size decision tree asks whether the drug substance will be used in a solid dosage form or in a liquid product containing undissolved drug substance.

If particle size has no meaningful effect on these attributes, a drug-substance particle-size acceptance criterion may not be necessary.

Polymorphism

Polymorphism is the occurrence of different crystalline forms of the same drug substance. It may also include:

• Hydrates
• Solvates
• Pseudopolymorphs
• Amorphous forms

Different solid forms may have different:

• Solubility
• Melting point
• Dissolution behavior
• Stability
• Processability
• Bioavailability

Common characterization techniques include:

• X-ray powder diffraction
• Differential scanning calorimetry
• Thermogravimetric analysis
• Differential thermal analysis
• Solid-state infrared spectroscopy
• Raman spectroscopy
• Microscopy
• Solid-state nuclear magnetic resonance

A polymorph should generally be included in the specification when its presence or conversion can affect product safety, performance, efficacy, stability, or bioavailability.

For finished products, a performance test such as dissolution may sometimes provide adequate control of polymorphic changes. Direct polymorph testing in the drug product is technically difficult and should not automatically be selected when a validated surrogate performance test is sufficient.

Chiral Quality

Chiral drug substances may require additional controls for:

• Chiral identity
• Chiral assay
• The opposite enantiomer
• Enantiomeric impurities

For a single-enantiomer drug substance, the specification may include:

• A chiral identity procedure
• A chiral assay
• An enantiomeric impurity test

An achiral assay combined with a validated procedure for controlling the opposite enantiomer may be an acceptable alternative when scientifically justified.

For racemic drug substances, stereospecific identity testing may be needed when:

• There is a realistic possibility of substitution of one enantiomer for the racemate
• Preferential crystallization may produce a non-racemic mixture

Finished-product stereospecific testing may not be necessary when racemization has been demonstrated to be insignificant during manufacturing and storage.

Water Content

Water-content testing is particularly important when the drug substance:

• Is hygroscopic
• Degrades in the presence of moisture
• Exists as a stoichiometric hydrate
• Changes physical properties after water absorption

Loss on drying may be suitable in some cases. Karl Fischer titration is generally preferred when a specific measurement of water is needed.

Inorganic Impurities

Inorganic impurity controls should be based on process knowledge and development studies.

Potential tests include:

• Sulfated ash
• Residue on ignition
• Catalyst residues
• Elemental impurities
• Atomic absorption spectroscopy
• Other suitable elemental procedures

Microbial Limits

Depending on the nature, manufacture, and intended use of the drug substance, microbial controls may include:

• Total aerobic microbial count
• Total yeast and mold count
• Absence of objectionable organisms
• Sterility
• Bacterial endotoxins

Examples of objectionable organisms may include Staphylococcus aureus, Escherichia coli, Salmonella, and Pseudomonas aeruginosa.

Specific Tests for Drug Products

Tablets and Hard Capsules

Dissolution

Dissolution testing is normally included for solid oral dosage forms because it measures the release of the drug substance from the dosage form.

Typical approaches include:

• Single-point testing for many immediate-release products
• Multiple time points for extended-release products
• Two-stage or sequential testing for delayed-release products

Dissolution conditions should be capable of identifying clinically unacceptable batches when dissolution has a meaningful effect on bioavailability.

Disintegration

Disintegration may replace dissolution in limited situations, particularly when:

• The drug is highly soluble throughout the physiological pH range
• The product dissolves rapidly
• A meaningful relationship between disintegration and dissolution has been demonstrated
• The formulation and manufacturing process are sufficiently robust

The decision should be supported by development data rather than based only on the dosage form.

Hardness and Friability

Hardness and friability are normally treated as in-process controls for tablets.

They may need to become specification tests when they have a direct and critical effect on product quality, such as with:

• Chewable tablets
• Tablets requiring special mechanical performance
• Products where mechanical strength affects clinical performance

Uniformity of Dosage Units

Uniformity of dosage units may be demonstrated through:

• Mass variation
• Content uniformity

In general, one approach rather than both should be selected unless there is a justified reason to use both.

When weight variation is used, development studies should demonstrate adequate blend and dosage-unit homogeneity.

Water Content

Water content should be included when moisture affects:

• Stability
• Hardness
• Dissolution
• Chemical degradation
• Physical properties
• Packaging performance

Loss on drying or Karl Fischer titration may be selected according to the product and the nature of the water present.

Microbial Limits

Microbial limits are both a quality-assurance consideration and a cGMP consideration.

Routine testing may be reduced or omitted for some solid oral products when:

• Components are adequately controlled
• The manufacturing process is validated
• The product does not support microbial growth
• Scientific evidence demonstrates a low contamination risk

The decision should be supported by documented development and validation data.

Oral Liquids and Powders for Reconstitution

Potential specification tests include:

• Uniformity of dosage units
• pH
• Microbial limits
• Antimicrobial preservative content
• Antioxidant content
• Extractables
• Alcohol content
• Dissolution
• Particle-size distribution
• Redispersibility
• Viscosity or other rheological properties
• Reconstitution time
• Water content

Antimicrobial Preservatives

For oral liquids containing antimicrobial preservatives, the minimum specified preservative concentration should be shown to maintain microbiological quality throughout use and shelf life.

Preservative effectiveness should be demonstrated using an appropriate pharmacopoeial procedure.

Extractables

Extractables from packaging components may require testing when the formulation is packaged in:

• Plastic bottles
• Non-glass containers
• Glass containers with non-glass closures
• Systems containing rubber or polymeric components

Testing may be reduced or eliminated when development and stability data demonstrate that extractables remain consistently below scientifically acceptable safety levels.

Any change to the formulation or container-closure system should trigger a reassessment.

Particle Size and Redispersibility

For oral suspensions, particle size may affect:

• Dose uniformity
• Sedimentation
• Dissolution
• Bioavailability
• Physical stability

Redispersibility testing may be appropriate when sediment forms during storage. The shaking procedure and the time required to achieve uniform resuspension should be clearly defined.

Parenteral Drug Products

Potential parenteral specification tests include:

• Uniformity of dosage units
• pH
• Sterility
• Bacterial endotoxins or pyrogens
• Visible and subvisible particulate matter
• Water content
• Preservative content
• Antioxidant content
• Extractables
• Delivery-system functionality
• Osmolarity
• Particle-size distribution for suspensions
• Redispersibility
• Reconstitution time

Sterility

Parenteral products should have a sterility test procedure and acceptance criterion unless an approved parametric-release approach is applicable.

Endotoxins and Pyrogens

An endotoxin test, such as a bacterial endotoxin test, should generally be included for parenteral products. Pyrogen testing may be considered as an alternative when scientifically justified.

Particulate Matter

Parenteral products should have suitable controls for:

• Visible particles
• Clarity
• Subvisible particles

The selected procedures should reflect the dosage form, container, formulation, and route of administration.

Delivery-System Functionality

For products packaged in prefilled syringes, cartridges, or autoinjectors, functionality testing may include:

• Syringeability
• Seal integrity
• Leakage
• Tip-cap removal force
• Piston-release force
• Piston-travel force
• Injector function

These attributes may be reduced to skip-lot or in-process testing only when supported by development and validation data.

Important General Concepts in ICH Q6A

Periodic or Skip Testing

Skip testing means performing a specified test on selected batches or at predetermined intervals instead of testing every batch.

Unscheduled batches must still meet the approved acceptance criteria if tested.

Skip testing should be:

• Scientifically justified
• Supported by sufficient historical and process data
• Presented to the regulatory authority
• Approved before implementation

It may be considered for attributes such as:

• Residual solvents
• Microbial limits
• Particle size
• Redispersibility
• Rheological properties

If a skip-tested batch fails, the failure should be investigated and reported as required. Routine batch-by-batch testing may need to be reinstated.

Release Versus Shelf-Life Acceptance Criteria

Release criteria apply when the batch is released. Shelf-life criteria apply throughout the approved storage period.

A manufacturer may use tighter internal release limits to provide greater assurance that the product will remain within its shelf-life limits.

This approach may be relevant for:

• Assay
• Degradation products
• Other stability-sensitive attributes

Regional regulatory requirements should always be checked before applying separate release and shelf-life criteria.

In-Process Tests

In-process tests are performed during manufacture rather than as part of the final release testing panel.

Examples include:

• Tablet hardness
• Tablet friability
• Individual tablet weight
• In-process pH
• Blend uniformity
• Process viscosity

A test may satisfy a specification requirement when:

• The test result is equivalent to or tighter than the release requirement
• The relationship between the in-process result and final product quality is demonstrated
• The method and sampling approach are validated

Tests used only to adjust a process within its operating range do not automatically become finished-product specification tests.

Parametric Release

Parametric release is an approved alternative to routine end-product testing in specific circumstances.

The guideline gives terminal sterilization as an example. A batch may be released based on satisfactory control of validated sterilization parameters such as:

• Temperature
• Pressure
• Time

Parametric release requires:

• A validated sterilization process
• Reliable monitoring and recording systems
• Defined acceptance criteria
• Maintenance of the validated state
• Periodic revalidation
• Regulatory approval

Parametric release is not a shortcut for avoiding quality testing. The indirectly controlled attribute, such as sterility, should still be identified in the specification with a reference to the associated procedure.

Alternative Analytical Procedures

An alternative analytical procedure may be used when it controls product quality to an extent comparable to or better than the official procedure.

For example, a spectrophotometric assay may be used for release when development data demonstrate that degradation does not occur during manufacture. A chromatographic procedure may still be necessary during shelf-life testing or for demonstrating impurity control.

Any alternative method should be:

• Scientifically justified
• Suitable for its intended purpose
• Validated
• Demonstrated to provide reliable quality control
• Acceptable to the relevant regulatory authority

Pharmacopoeial Procedures

Where appropriate, pharmacopoeial procedures and acceptance criteria should be used.

Relevant compendia may include:

• USP
• European Pharmacopoeia
• JP

When procedures have been harmonized, the corresponding pharmacopoeial methods may be considered interchangeable as described by the relevant compendial harmonization arrangements.

However, the current monograph, local adoption status, method suitability, and regulatory expectations should always be verified.

Evolving Analytical Technologies

ICH Q6A recognizes that analytical technologies continue to develop.

New or modified technologies may be used when they:

• Improve assurance of quality
• Provide better specificity
• Improve sensitivity
• Offer more reliable process understanding
• Are scientifically justified and validated

Examples may include:

• High-resolution mass spectrometry
• Raman spectroscopy
• Near-infrared spectroscopy
• Multidimensional chromatography
• Advanced particle characterization
• Automated image analysis

Reference Standards

A reference standard is used in procedures such as:

• Assay
• Identification
• Purity testing
• Impurity quantification

The reference standard should have quality appropriate to its intended use. It may require additional characterization beyond routine testing.

For a new drug-substance assay standard:

• Impurities should be adequately identified or controlled
• Purity should be measured quantitatively
• Characterization should support the assigned value
• Storage and handling should be controlled

Reference-standard preparation, qualification, use, and replacement should be documented in a controlled SOP.

ICH Q6A Decision Trees Explained

Decision Tree 1: Specified Impurity in a New Drug Substance

The first decision tree establishes an approach for setting an acceptance criterion for a specified impurity.

Main steps:

1. Determine the impurity level in relevant development, pilot, and scale-up batches.
2. Calculate the mean plus the upper confidence limit, designated as A.
3. If the impurity is also a degradation product, estimate its maximum increase during the retest period using accelerated and long-term stability data.
4. Add the expected increase to A to calculate the maximum likely level, designated as B.
5. Compare A or B with the qualified level.

The uploaded decision tree describes the upper confidence limit as three times the standard deviation of batch-analysis data.

If the expected impurity level does not exceed the qualified level, the acceptance criterion may be based on A or B, as appropriate.

If the expected level exceeds the qualified level, the applicant may need to:

• Use the qualified level
• Establish a new qualified level
• Generate additional qualification data
• Reconsider the process or storage conditions

Decision Tree 2: Degradation Product in a New Drug Product

The second decision tree addresses degradation products in the finished product.

Main steps:

1. Determine whether degradation occurs during product manufacture.
2. If it does, estimate the manufacturing increase as C.
3. Estimate the increase during shelf life as D.
4. Determine the maximum likely level using the drug-substance acceptance criterion and the expected increases.

Maximum likely level = A or B + C + D

5. Compare the maximum likely level with the qualified level.

If the expected level is too high, possible actions include:

• Establishing a new qualified level
• Changing storage conditions
• Reducing shelf life
• Improving the formulation or manufacturing process

Decision Tree 3: Drug-Substance Particle Size

A particle-size acceptance criterion should be considered when the drug substance is used in:

• A solid dosage form
• A liquid product containing undissolved drug substance

The criterion may be necessary if particle size affects:

• Dissolution
• Solubility
• Bioavailability
• Processability
• Stability
• Content uniformity
• Product appearance

If none of these attributes is affected, a drug-substance particle-size acceptance criterion may not be needed.

Decision Tree 4: Polymorphism

The polymorphism decision tree is applied in stages.

Drug substance stage:

1. Conduct a polymorphism screen.
2. Determine whether different forms can be produced.
3. Characterize the forms using suitable solid-state techniques.
4. Determine whether the forms have different properties.
5. Assess whether product safety, performance, or efficacy is affected.

If different forms do not have meaningful property differences, no further polymorphism test may be needed.

If the forms affect product quality or performance, a polymorph-content acceptance criterion may be appropriate for the drug substance.

Drug product stage:

For the finished product, determine whether routine performance testing, such as dissolution, adequately controls changes in polymorph ratio.

If performance testing is adequate, acceptance criteria may be established for the relevant performance test.

If not, polymorphism should be monitored during stability studies. A finished-product polymorph criterion is needed only when a change could affect safety or efficacy.

Decision Tree 5: Chiral Identity, Assay, and Enantiomeric Impurities

The chiral decision tree determines whether stereospecific controls are needed.

For a non-chiral drug substance, chiral identity, assay, and impurity procedures are not required.

For a single-enantiomer drug substance, the specification may require:

• Chiral identity
• Chiral assay
• Enantiomeric impurity control

For the drug product, chiral assay and enantiomeric impurity testing may be needed unless racemization has been shown to be insignificant.

For racemic products, stereospecific identity testing may be important when there is a risk of enantiomer substitution or preferential crystallization.

Decision Tree 6: Microbiological Quality of Drug Substances and Excipients

The microbiological decision tree asks:

1. Can the material support microbial growth or viability?
2. Is the material sterile?
3. Does processing inherently reduce microorganisms?
4. Is there scientific evidence that microbial levels remain below the applicable limits?
5. Are monitoring results consistently below acceptance criteria?

Possible outcomes include:

• No microbial-limit testing when strong supporting data are available
• Routine microbial-limit testing
• Testing for specified objectionable organisms
• Skip-lot testing
• Lot-by-lot testing

A sterile material may not need additional microbial-limit acceptance criteria under this decision pathway, although its sterility controls remain important.

Decision Tree 7: Drug-Product Dissolution

The dissolution decision tree contains three parts.

Part 1: Selecting the type of release criterion

For modified-release products:

• Extended-release products generally require multiple time points.
• Delayed-release products may require two-stage testing, either sequential or parallel.

For immediate-release products, the decision depends on solubility and dissolution rate.

The Q6A decision tree considers a drug highly soluble when the dose-to-solubility volume is no more than 250 mL across pH 1.2 to 6.8 at approximately 37 °C.

A rapidly dissolving product is described as one in which at least 80% of the labeled amount dissolves within 15 minutes in media at pH 1.2, 4.0, and 6.8.

When a highly soluble product dissolves rapidly and a reliable relationship exists between disintegration and dissolution, a disintegration criterion may be appropriate.

Part 2: Immediate-release test conditions

If dissolution significantly affects bioavailability, the method should distinguish batches with unacceptable bioavailability.

If dissolution does not significantly affect bioavailability:

• The test should pass clinically acceptable batches.
• If formulation or process changes affect dissolution, the method may need to distinguish those changes.
• If another specification already controls the change, a highly discriminating dissolution test may not be necessary.
• Single-point criteria are generally acceptable for many immediate-release products.

Part 3: Extended-release acceptance ranges

For extended-release products, acceptance ranges should be based on:

• Bioavailability data
• Stability data
• Clinical data
• Batch-release data
• In vitro/in vivo relationships
• The sensitivity of the dissolution method

When a reliable in vitro/in vivo relationship is available, it may be used with appropriate batch data to establish acceptance ranges.

The guideline also discusses a total numerical variability of approximately 20% of labeled content, represented by ±10% at a given time point, unless a wider range is supported by appropriate bioavailability or bioequivalence data.

Decision Tree 8: Microbiological Attributes of Non-Sterile Products

For non-sterile drug products, the decision tree considers:

• Whether the product is a dry dosage form
• Whether it has growth-inhibitory properties
• Whether it contains antimicrobial preservatives
• Whether it has inherent antimicrobial activity
• Whether production lots consistently meet microbial limits

Dry dosage forms may not require routine microbial-limit testing when scientific evidence demonstrates that they do not support microbial growth.

For products that contain antimicrobial preservatives, the specification should address preservative content. Preservative effectiveness should be demonstrated at the minimum specified concentration.

When microbial limits are necessary, testing may initially be performed on every lot. Consistently satisfactory results may support skip-lot testing or a justified reduction in routine testing.

Practical Workflow for Developing an ICH Q6A Specification

1. Define the Product and Intended Use

Identify:

• Drug substance or drug product
• Dosage form
• Route of administration
• Immediate- or modified-release design
• Sterile or non-sterile status
• Intended storage conditions
• Container-closure system

2. Assemble Development and Manufacturing Data

The justification should consider:

• Laboratory development batches
• Toxicology batches
• Clinical batches
• Pilot batches
• Scale-up batches
• Process-validation batches
• Stability batches
• Manufacturing-site data
• Analytical variability
• Manufacturing variability

3. Select Universal Tests

Evaluate the need for:

• Description
• Identification
• Assay
• Organic impurities
• Inorganic impurities
• Residual solvents
• Degradation products

4. Select Product-Specific Tests

Consider whether the product requires:

• Dissolution
• Disintegration
• Particle-size distribution
• Polymorphism
• Chiral testing
• Water content
• Microbial limits
• Sterility
• Endotoxins
• Preservative content
• pH
• Viscosity
• Redispersibility
• Reconstitution time
• Extractables
• Particulate matter
• Delivery-system functionality

5. Develop and Validate Analytical Procedures

Methods should be fit for purpose and capable of measuring the relevant attribute with appropriate:

• Specificity
• Accuracy
• Precision
• Linearity
• Detection capability
• Range
• Robustness
• Stability-indicating performance

The method should be linked to a controlled SOP, sampling plan, calculation procedure, and reporting format.

6. Justify Acceptance Criteria

Each test and acceptance criterion should be supported by appropriate evidence, including:

• Development results
• Stability trends
• Clinical and toxicology batch results
• Manufacturing variability
• Analytical variability
• Process capability
• Pharmacopoeial standards
• In vivo performance
• Safety and efficacy considerations

Acceptance criteria should not simply be copied from a small number of early batches.

7. Qualify Laboratory Equipment

Analytical equipment used to generate specification data should be appropriately qualified.

A practical qualification pathway may include:

• URS
• DQ
• IQ
• OQ
• PQ

Qualification does not replace analytical-method validation, but it supports the reliability of the instruments and systems used to produce specification data.

8. Control Data and Documentation

Raw data, calculations, chromatograms, spectra, audit trails, standards, and laboratory records should be controlled according to ALCOA+ principles.

The specification should clearly identify:

• Routine batch-by-batch tests
• In-process tests
• Periodic tests
• Skip-lot tests
• Test frequency
• Sampling requirements
• Reference methods
• Alternative procedures
• Reporting responsibilities

9. Establish a Review and Change-Control System

Specifications may need revision as additional experience becomes available.

Changes may involve:

• Tightening criteria
• Loosening criteria
• Adding a new test
• Removing a test
• Changing test frequency
• Revising an analytical method
• Changing the container-closure system
• Revising the shelf life

Some changes may require prior regulatory approval. Applicable regional requirements, including relevant 21 CFR provisions, should be assessed.

10. Investigate Failures Properly

A failure against an approved acceptance criterion should be investigated through a documented procedure.

The investigation should assess:

• Laboratory error
• Sampling error
• Equipment performance
• Method suitability
• Manufacturing variation
• Raw-material variability
• Stability trends
• Product impact

Where appropriate, corrective and preventive action should be managed through a formal CAPA new system.

Common Mistakes When Applying ICH Q6A

Treating Every Development Test as a Specification Test

Development studies are often broader than routine release testing. A test should become part of the specification only when it provides meaningful control of product quality.

Copying Acceptance Criteria Without Product Data

Pharmacopoeial standards and historical limits may provide useful context, but product-specific development and stability data are still necessary.

Using a Single Retention Time for Identification

A single chromatographic retention time may not distinguish the active substance from related compounds. Orthogonal or more specific identification approaches may be necessary.

Ignoring Process and Analytical Variability

Acceptance criteria should account for reasonable manufacturing and analytical variability. Criteria that merely describe a small early batch set may not be suitable for commercial production.

Confusing In-Process Controls With Release Tests

Hardness, friability, viscosity, particle size, and pH may be in-process tests, release tests, or both, depending on their relationship to final product quality.

Applying Skip Testing Without Approval

Skip testing is not an informal reduction in laboratory workload. It requires scientific justification, regulatory acceptance, monitoring, and a defined response to failure.

Treating Parametric Release as a Shortcut

Parametric release is based on a validated process and reliable critical-parameter monitoring. It should not be used to avoid weak or incomplete sterility assurance.

Failing to Reassess Packaging Changes

Changes to the container-closure system can affect:

• Extractables
• Moisture
• Oxygen exposure
• Preservative stability
• Particulate matter
• Product functionality

The specification and testing strategy should be reassessed after such changes.

Key Takeaways

• The ICH Q6A guideline provides a framework for specifications for new chemical drug substances and products.
• A specification combines tests, analytical procedures, and acceptance criteria.
• Specifications are part of a wider control strategy that includes development, GMP, validation, and stability.
• Universal tests commonly include description, identification, assay, and impurities.
• Specific tests depend on dosage form, product characteristics, and intended use.
• Particle size, polymorphism, chiral quality, microbial limits, and dissolution require product-specific evaluation.
• Acceptance criteria should be based on development, stability, manufacturing, clinical, and analytical data.
• Skip testing and parametric release require scientific justification and regulatory approval.
• In-process testing may satisfy a specification requirement when the relationship to final quality is demonstrated.
• The eight Q6A decision trees support structured decisions for impurities, degradation, particle size, polymorphism, chiral quality, microbial quality, and dissolution.
• Specifications should be reviewed when manufacturing, formulation, analytical methods, packaging, or storage conditions change.

Frequently Asked Questions

1. What is the ICH Q6A guideline?

The ICH Q6A guideline provides recommendations for establishing test procedures and acceptance criteria for new chemical drug substances and drug products. It explains how specifications should be selected, scientifically justified, and applied during release and shelf life.

2. What does an ICH Q6A specification contain?

An ICH Q6A specification contains a list of tests, references to analytical procedures, and acceptance criteria. Acceptance criteria may be numerical limits, ranges, or other scientifically justified requirements used to determine whether a drug substance or product is acceptable.

3. What are the universal tests under ICH Q6A?

The main universal tests are description, identification, assay, and impurity testing. These tests are potentially applicable to most new drug substances and drug products, although the analytical method and acceptance criteria must be justified for each product.

4. Does ICH Q6A apply to biological products?

ICH Q6A is intended mainly for chemical drug substances and products. It is not sufficient by itself for higher molecular weight peptides, polypeptides, or biotechnological and biological products. A separate ICH guideline for biotechnological and biological products should be considered.

5. When is particle-size testing required?

Particle-size testing may be required when particle size affects dissolution, solubility, bioavailability, processability, stability, content uniformity, or product appearance. If none of these attributes is affected, a particle-size acceptance criterion may not be necessary.

6. Can disintegration replace dissolution testing?

Disintegration may replace dissolution for certain rapidly dissolving immediate-release products containing highly soluble drugs when development studies demonstrate a reliable relationship between disintegration and dissolution. The approach requires scientific justification and regulatory acceptance.

7. What is skip testing under ICH Q6A?

Skip testing is testing performed on selected batches or at predetermined intervals instead of every batch. It may be considered when historical and development data demonstrate consistent control. Skip testing requires justification, approval, monitoring, and a defined response to failure.

8. What is the difference between release and shelf-life acceptance criteria?

Release acceptance criteria apply when a batch is released, while shelf-life criteria apply throughout the approved storage period. A manufacturer may use tighter internal release limits to provide additional assurance that the product will remain within its shelf-life limits.

9. When should polymorphism be included in a specification?

Polymorphism should be included when different solid forms have different properties and those differences can affect product safety, efficacy, stability, bioavailability, or performance. A performance test such as dissolution may sometimes provide adequate control instead of direct polymorph testing.

10. How are dissolution acceptance criteria established?

Dissolution acceptance criteria depend on dosage form, solubility, dissolution rate, bioavailability, formulation variables, manufacturing variables, stability data, and any in vitro/in vivo relationship. Immediate-release products often use single-point criteria, while modified-release products generally require multiple time points or staged testing.

Conclusion

The ICH Q6A guideline provides a structured and science-based approach for establishing specifications for new chemical drug substances and drug products. Its central principle is that each test and acceptance criterion should have a clear connection to product quality, safety, efficacy, process understanding, or performance.

The guideline does not prescribe one universal specification for every product. Instead, it encourages manufacturers to use development data, stability results, manufacturing experience, analytical capability, pharmacopoeial knowledge, and clinical evidence to create appropriate controls.

When applied correctly, Q6A helps companies distinguish between universal and product-specific tests, determine when dissolution or particle-size controls are necessary, manage impurities and degradation products, evaluate polymorphism and chiral quality, and develop scientifically justified microbiological strategies.

A well-designed Q6A specification should therefore be viewed as a living component of the pharmaceutical quality system, supported by ICH Quality Guidelines, validated procedures, reliable data, effective change control, and continuous manufacturing knowledge.

Source note: This article is based on the uploaded ICH Q6A Guideline and ICH Q6A Decision Tree documents. Always verify current regional regulatory requirements and applicable pharmacopoeial editions before using the information in a regulatory submission or approved specification.